Morgan Stanley analyst Terence Flynn has reiterated a "Buy" rating on Gilead Sciences (GILD.US), setting a price target of $143. The analyst highlighted that the U.S. Centers for Disease Control and Prevention (CDC) has recently included Gilead's Yeztugo in its recommended medications for HIV pre-exposure prophylaxis (PrEP). Flynn views this endorsement as authoritative validation of the drug's efficacy and safety profile. Furthermore, he believes the CDC recommendation will enhance patient adherence to treatment protocols, strengthen HIV prevention outcomes, and subsequently drive increased market demand for Yeztugo. Concurrently, Gilead Sciences is actively advancing commercial insurance coverage initiatives for Yeztugo, with expectations that the medication will secure comprehensive insurance reimbursement support by the end of 2025. As a biopharmaceutical company, Gilead Sciences focuses on developing treatments for serious diseases, with research and development efforts spanning HIV, viral hepatitis, COVID-19, and oncology.